---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-088752"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:56:47.968015+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sana reports positive six-month data for islet cell therapy in type 1 diabetes without immunosuppression

## Summary
- Six-month results: transplanted allogeneic islet cells (UP421) safe, survive, evade immune system, produce insulin without immunosuppression.
- C-peptide detectable fasting and increases with mixed meal tolerance test, confirming insulin secretion; MRI shows graft survival at 6 months.
- No safety issues; HIP-modified cells evade both allogeneic and autoimmune responses in type 1 diabetes patient.
- Sana plans to file IND for SC451 (stem cell-derived HIP islet therapy) as soon as next year, incorporating UP421 learnings.
- Data presented at ADA 85th Scientific Sessions; study funded by Helmsley Charitable Trust, partnership with Uppsala University Hospital.

## SEC filing metadata
- accession: 0000950170-25-088752
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000095017025088752/0000950170-25-088752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000095017025088752/sana-20250623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-088752
- JSON: https://secwatch.observer/filing/0000950170-25-088752.json
- Plain text: https://secwatch.observer/filing/0000950170-25-088752.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.